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Background: To evaluate the treatment with topical 0.05% cyclosporine A (CsA) in patients with subepithelial
corneal infiltrates (SEI).
Methods: We reviewed 16 patients (22 eyes) before and after the treatment with 0.05% CsA eye drops. All patients
had been treated previously with topical corticosteroids without any improvement and also they had to stop the
medication secondary to intraocular pressure elevation. The objective data recorded included best-corrected visual
acuity (BCVA), evaluation of corneal subepithelial infiltrate scores (CSIS), intraocular pressure (IOP) prior to treatment
and the last follow-up visit.
Results: Six males (37.5%) and 10 females (62.5%), mean age of 35.2 ± 16.6 years, were included. The patients’
average topical CsA use duration was 5.1 ± 3.5 months (1 – 13 months). The average follow up time of the patients
was 9.2 ± 4.7 months (4 – 22 months). One patient, although he didn’t have a 0 scale of SCIS, did not show up for
follow up examinations after six months. The mean BCVA (logarithm of the minimum angle of resolution) before
and after the treatment were 0.15 ± 0.15 and 0.07 ± 0.07 respectively, CSIS 1.68 ± 0.89 and 0.23 ± 0.53 respectively,
IOP 18.50 ± 3.82 and 16.86 ± 2.76 mmHg respectively. There were statistically significant improvements in BCVA
(p = 0.002), reduction of CSIS (p = 0.002) and reduction of IOP (p < 0.001) prior to treatment and the last follow-up
visit. 18 eyes (81.9%) showed clinical improvement and 4 (18.1%) had decreased SEI which did not fully disappear
during the treatment period. The eyes which reached CSIS score 0 (18 eyes) were treated with CsA for
1 – 13 months; while the eyes which had clinical improvement but had not CSIS score 0 (4 eyes) were decided to
discontinue of CsA treatment in last follow-up visit. There were recurrences in 2 eyes 3 months after the treatment.
Patients reported reduction in the severity of symptoms after the treatment. Most of the patients reported no
foreign body sensation, glare, or other side effects with topical CsA treatment. Overall, patients noted an
improvement in vision and satisfaction with topical 0.05% CsA treatment.
Conclusions: Topical 0.05% CsA is a safe and effective alternative treatment in patients with SEI who do not
respond to other treatment modalities or have undesired side effects from topical steroids.
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Epidemic keratoconjunctivitis (EKC) is one of the most
common ocular viral infections caused by adenoviruses.
Adenovirus family consists of different serotypes. Sero-
types 8, 11 19 and 37 are held responsible for EKC and
it is known that especially serotypes 8 and 19 cause epi-
demics [1,2]. Disease presents itself after an incubation
period which usually takes 2 to 14 days. Mixed papillary
and follicular response of the conjunctiva, eye pain,
burning eyes, itching of the eyes, diffuse hyperemia, che-
mosis, serous discharge and ipsilateral periauricular
lymphadenopathy can be observed during the course of
the disease. In approximately 80% of the cases, keratitis
in the form of diffuse superficial punctate keratitis, focal
epithelial punctate keratitis, and subepithelial infiltrates
(SEI) follow the conjunctivitis in a manner of 1 to
3 weeks. Subepithelial infiltrates are small, round and
grayish lesions. They are composed of residues of anti-
gen and lymphocyte accumulations adhered to surface
stromal cells. The lesions disappear without causing
scarring or neovascularization. They are usually bilateral
and frequently asymmetrical. They may stay dormant in
the cornea for months or years, or they may cause acute
symptoms such as decrease in visual acuity, halo, glare,
and photophobia [3,4]. Topical corticosteroids may sup-
press the symptoms and findings of EKC, however due
to extended use of these agents problems such as cata-
ract, glaucoma, and tendency to super infections may
occur [5-7].
There are reports that show the efficacy of topical CsA
(with concentrations of 1% and 2%) in the acute phase
of adenoviral infections in the therapy of early local
symptoms and in decreasing the incidence of corneal
opacities and in the therapy of active subepithelial infil-
trates during the chronic phase [3,8-10]. However, there
are no detailed studies performed with topical 0.05%
CsA in the therapy of corneal subepithelial infiltrates.
The aim of this study was to assess the efficiency of top-
ical 0.05% CsA (RestasisW, Allergan, Irvine, California,
USA) in treating the corneal subepithelial infiltrates that
have persisted for more than three months in patients
with adenoviral epidemic keratoconjunctivitis.
Methods
This study was performed on the 22 eyes of 16 patients
who were referred to our clinics between the dates of
September 2007 and October 2011, and who had sube-
pithelial infiltrates following epidemic keratoconjunctivi-
tis that persisted more than three months and who did
not adequately respond to topical corticosteroids or in
whom 3 of the corticosteroids were discontinued due to
their side effects and 0.05% topical CsA were started.
Age, gender, affected eyes, BCVA (logarithm of the mini-
mum angle of resolution [LogMAR]) measurementsprior to and after the treatment, IOP measurements
(with non contact tonometers) were recorded and
detailed biomicroscopic anterior segment examinations
were performed. The corticosteroids used, average cor-
ticosteroid use, topical 0.05% CsA use durations and me-
dian follow up durations were recorded. Corneal
subepithelial infiltrate scoring (CSIS) that varied between
0 and 4 were constituted according to the number of
SEI seen in biomicroscopic examinations (0: no infiltrate,
1: 1–5, 2: 6 – 10, 3: 11 – 15, 4: more than 16 infiltrates)
[11]. All patients were treated with topical 0.05% CsA
(RestasisW) for a month as follows: 4 times a day of top-
ical 0.05% CsA (RestasisW), in addition to the topical
corticosteroids they were using for the first 15 days, and
then 2 times a day of topical 0.05% CsA (RestasisW) after
topical corticosteroids were discontinued. At the end of
the first month, treatment was discontinued in those
patients with a CSIS of 0 and monitorization of these
patients began. In the patients with CSIS other than 0
were continued on topical 0.05% CsA (RestasisW) ther-
apy either once a day or once in every other day accord-
ing to the symptom intensity and clinical examination
results.
All analysis were carried out by SPSS 17.0 (Statistical
Package for Social Sciences Inc. Chicago, IL, USA) soft-
ware. Wilcoxon signed rank test was used for statistical
analysis and values of p < 0.05 were considered to be sig-
nificant. Gaziantep University Ethics Committee ap-
proval and informed consent form from the participants
were attained.
Results
Twenty-two eyes of sixteen patients were included in
the study, of these 6 (37.5%) were male and 10 (62.5%)
were female. The average age of the patients was
35.2 ± 16.6 years (13 – 75 years). Subepithelial infiltrates
were located in the right eye in 14 patients whereas 8
patients had them in the left eye. Prior to treatment,
BCVA was 0.00 LogMAR in 10 eyes and there were
varying degrees of visual loss in 12 eyes with values of
0.40 – 0.10 logMAR. Prior to therapy, average intraocu-
lar pressures were recorded to be 18.50 ± 3.82 mmHg
(11 – 26 mmHg), and average CSIS scores were
1.68 ± 0.89 (Table 1). The average duration of cortico-
steroid use of the patients was 6.7 ± 3.9 months
(3–14 months). Fluorometholone therapy was performed
on eleven eyes, Loteprednol etabonate on nine eyes and
Prednisolone asetate on two eyes. Before receiving top-
ical CsA therapy, 8 eyes of 7 patients were on anti -
glaucomatous therapy. After the first month, CSIS scale
was found to be 0 in all eight eyes. In these patients, the
treatment was discontinued and follow up of the
patients began after this time interval. There was no re-
currence during the follow up period in eight eyes. In 14










































1 13/F RE 0.00 11 1 12 Y 1 0.00 11 0 6 N
2 38/F LE 0.00 14 1 9 N 6 0.00 12 0 5 N
3 26/F RE/LE 0.10/0.22 16/18 1/2 3/5 N 1/1 0.00/0.10 14/19 0/0 4/3 N
4 47/F RE 0.00 15 1 3 N 7 0.00 17 0 2 N
5 40/F RE 0.22 25 1 3 Y 1 0.00 20 0 4 N
6 30/M RE/LE 0.40/0.00 26/22 4/1 4/7 Y 13/8 0.20/0.00 21/19 2/0 5/3 N
7 18/M RE 0.40 23 3 6 Y 7 0.15 20 1 2 N
8 50/M RE 0.22 18 2 7 N 6 0.10 16 1 0 N
9 27/M RE/LE 0.00/0.30 15/17 1/3 8/9 N 1/1 0.00/0.15 13/16 0/0 3/3 N
10 40/F LE 0.00 19 2 4 N 7 0.00 19 0 3 Y
11 16/M RE 0.00 17 1 3 N 6 0.00 14 0 4 N
12 32/F RE 0.20 16 1 3 N 1 0.10 17 0 3 N
13 75/M RE/LE 0.00/0.20 15/22 1/2 5/4 Y 7/8 0.00/0.15 16/19 0/0 4/3 Y
14 60/F RE 0.00 20 1 11 Y 6 0.00 19 0 10 N
15 30/F RE/LE 0.40/0.30 17/21 3/2 13/8 N 10/8 0.20/0.10 15/18 1/0 12/3 N
16 22/F RE/LE 0.00/0.30 17/23 1/2 14/10 Y 1/5 0.00/0.10 17/19 0/0 6/4 N
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every other day was continued depending on the sub-
jective symptoms of the patients (halo, glare and photo-
phobia etc.) and their examination findings (BCVA,
CSIS) (Table 1). In one eye with a CSIS scale of 2, in two
eyes with a CSIS scale of 3 and one eye with a CSIS scale
of 4 at the start, scale did not revert to 0 in spite of the
treatment. The average topical CsA use duration of the
patients was 5.1 ± 3.5 months (1–13 months) (Table 1).
The average follow up time of the patients was
9.2 ± 4.7 months (4 – 22 months). One patient, though
not having a 0 scale of SCIS, did not show up for follow
up examinations after six months. In the last control,
the average BCVA was recorded to be 0.07 ± 0.07,
whereas IOP was 16.86 ± 2.76 mmHg and CSIS was 0.
23 ± 0.53, respectively. When the average BCVA, CSIS
and IOP values prior to the therapy and in the last
control were compared, there was a statistically signifi-
cant difference among them [(p = 0.002), (p = 0.002),
(p < 0.001), respectively] (Table 2). In the last control
exam, symptoms such as glare, photophobia and dis-
comfort in the eye that were present in 18 eyes (81.8%)
were completely resolved. In 4 eyes (18.2%), which still
had subepithelial infiltrates, photophobia and glare were
still present. There were no eyes on anti-glaucomatous
therapy during the last control examinations. The aver-
age after discontinuation of medicine treatment was in
the period of 4.1 ± 2.6 months (0–12 months), at the end
of the first month of CsA discontinuation no recurrence
was observed in eight eyes however three months after
the discontinuation of medication recurrence was
observed in two eyes which had CsA medication for 7
and 8 months respectively (Table 1). In 16 of the 18 eyes
which were free of subepithelial infiltrates had no
recurrences.
Discussion
Epidemic keratoconjunctivitis (EKC) can present with
symptoms such as chemosis, eye pain, itching, hy-
peremia, photophobia and swelling of eyelids that can
have a negative effect on everyday life. In approximately
80% of the patients, keratitis with subepithelial infiltra-
tions (SEI) can ensue the conjunctivitis [3,4]. SEI canTable 2 Patient data before and after treatment with
0.05% CsA
Patient data Before CsA treatment After CsA treatment p
BCVA 0.15 ± 0.15 0.06 ± 0.07 0.002
IOP (mmHg) 18.50 ± 3.83 16.86 ± 2.76 0.002
CSIS 1.68 ± 0.89 0. 23 ± 0.53 <0.001
BCVA: Best corrected visual acuity (LogMAR), IOP: Intraocular pressure, CSIS:
Corneal subepithelial infiltrate scores, data are shown Mean±SD, Statistical
analysis for used Wilcoxon Signed Ranks test, p values less than 0.05 are
reported as statistically significant.result in a decrease of visual acuity, halo, irregular astig-
matism and photophobia. Some studies report that the
decrease in visual acuity caused by SEI can resolve in a
matter of weeks and that it can persist for years in some
cases [1,10]. In ocular adenovirus infections, virus static
agents; such as trifluridine, vidarabine and ganciclovir;
were tried but none were found to be effective in treat-
ment [12-14]. It is reported that long term corticosteroid
use in adenovirus infections are effective but can cause
cataracts, glaucoma and super infections [5-7].
Our study group consisted of patients who had no
regression in SEI in spite of corticosteroid use of
3–14 months (average 6.7 ± 3.9 months) and those who
had to stop the corticosteroids because of intraocular
pressure due to 5 long term use. There was enough
intraocular pressure to cause varying visual loss in
twelve eyes with values of 0.40 – 0.10 logMAR and anti
glaucomatous therapy to start in 8 eyes.
It is reported that topical CsA plays a role in the inhib-
ition of T lymphocyte proliferation and activation and
suppression of the inflammation of the ocular surface
lacrimal gland [15]. It is reported in the literature that
topical CsA is effective in various concentrations in ocu-
lar inflammation cases such as vernal keratoconjunctivi-
tis, ulcerative keratitis due to rheumatoid artritis,
Thygeson superficial punctate keratitis, anterior uveitis,
corneal graft rejection, superior limbic keratoconjuncti-
vitis, greft versus host disease, micotic keratitis, Cogan
syndrome, Behçet’s disease, herpetic stromal keratitis,
Mooren ulcer and atopic keratoconjunctivitis [16-30].
Topical 0.05% CsA was used in the treatment of dry eye
syndrome, in minimizing the risk of recurrence after
pterygium surgery, in treatment of ocular graft-versus-
host disease and in the treatment of meibomian gland
dysfunction successfully without any systemic or ocular
side effects [31-35]. In our study, there were improve-
ments in the signs and symptoms caused by SEIs,
that developed after EKC infections, by using topical
0.05% CsA and there were no ocular or systemic side
effects observed.
In studies conducted by using topical CsA in the treat-
ment of acute and chronic adenovirus infections, it was
reported that CsA was effective in concentrations of 1%
and 2% and that the SEI’s were completely obliterated
or majorly reduced after a 3 to 4 week therapy
[1,3,8-10,16]. After a one month topical 0.05% CsA ther-
apy, it was observed that in 8 (36.3%) eyes SEIs were
completely cleared, and in 10 eyes (45.45%) this result
was achieved in the last follow up visit. In remaining
4 eyes (18.2%) they were not completely cleared but
decreased in number. The treatment was discontinued
in the eyes with no SEI left, and it was continued in
doses of once a day or once in every other day in eyes
which still had SEIs.
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per day or every other day of 1% or 0.05% topical CsA
treatment following an initial therapy of topical 1% CsA
and steroids for a month was effective in SEI treatment
[9]. The average topical 0.05% CsA use of the patients
was 5.1 ± 3.5 months (1–13 months), and the follow up
time was 9.2 ± 4.7 months (4–22 months). The increase
in the visual acuity, decrease in CSIS score and the
intraocular pressure in the last follow up visit was sig-
nificant. There were no patients on antiglaucomatous
therapy. In the last follow up visit, 18 eyes out of 22
(81.8%) had a CSIS score of 0, and 4 (18.2%) eyes had a
decrease in SEI numbers. There were 2 recurrences out
of 18 eyes (11%) after the therapy was discontinued.
Reinhart and colleagues have reported that there were
amelioration and decrease in SEI number in the 48 eyes
out of 70 which had SEIs after EKC infection after a
therapy with 2% topical CsA, and there were no recur-
rences after therapy was discontinued [10]. In the litera-
ture, it has been reported that 1% topical CsA was
tolerated well and did not cause any systemic side effects
in long term follow ups [8,9]. Romanowski and collea-
gues reported that in their trials 0.5% and 2% topical
CsA treatments were effective in decreasing the number
of SEI formations, however it was claimed that this
agent could facilitate the risk of endemics by increasing
viral replication [11].
When the studies in the literature were analyzed, it
was observed that topical CsA of varying concentrations
between 0.5-2% were used in the inhibition of T
lymphocyte proliferation and activation and in eradicat-
ing the symptoms and minimizing the recurrences of
SEI in acute adenoviral infections. In chronic phases, it
is reported to be an effective and safe treatment of SEIs
and minimizing the recurrence risk. However, there were
no detailed studies concerning the corneal subepithelial
infiltration therapy with lesser concentrations of topical
0.05% CsA.
In this study, we had two recurrent cases (11.12%)
who were treated with topical CsA for 4 and 8 months.
While the average treatment time for all eyes was
5.1 ± 3.5 months. After 9.2 ± 4.7 months (4 – 22 months)
of treatment, only 2 eyes (recurrence in two eyes was
seen in 3rd month) out of 18 were detected as recurrent.
In 16 of the 18 eyes, which were free of subepithelial
infiltrates, had no recurrences. As for our experience,
treatment of SEI by using CsA should be continued until
the CSIS is seen as 0. However, whether SEI will recur
after treatment or when will it recur cannot be foreseen.
Therefore, follow up visit duration should be as longer
as possible. Further studies regarding the ideal follow up
visit duration after treatment with CsA is warranted.
The small number of the patients, the absence of control
group, and the retrospective design of the study seemsto be the limitations of this study. For treatment of SEI
development after EKC, two different treatment meth-
ods are used which were proven to be efficient are top-
ical korticosteroid and topical CsA. Because the patient
group was consisted of patients who did not benefit
from at least 3 months of treatment with topical corti-
costeroids or who develop steroid-related side effects;
current treatment could not be continued. Because the
clinical symptoms of patients affect their daily life, con-
trol group who will be treated with placebo could not be
constructed. However, the difficulty of building control
group for the cases with subepithelial infiltrates who do
not exert improvement in symptoms and findings after
3-month treatment with corticosteroids should be taken
into consideration. On the other hand, clinician must
choose and apply the most reliable treatment strategy
which resolve patient complaints and improves clinical
findings for SEI. Since our data were acquired without a
control group, we cannot resolve the possibility of spon-
taneous remission of SEI as the natural history of the
disease in this study.
A masked controlled study of topical 0.05% CsA in
human subjects with larger patient populations could
better define the natural history and effect of treatment
of this disorder. As an alternative approach, different
concentrations of CsA can be compared using different
treatment groups for prospective studies.
Conclusions
As a result, the authors claim that topical 0.05% CsA is a
safe and effective option in eradicating the symptoms of
adenovirus infections and in the therapy of cases which
have steroid resistant SEIs after chronic adenovirus
infections.
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